UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,700 people in approximately 40 countries, the company generated revenue of €5.5 billion in 2022. UCB is listed on Euronext Brussels.
“Training is a key element in UCB’s development! The continuous training and upskilling of our employees, as well as welcoming students in programs, are essential pillars for us. In recent months, we have been able to train some of our employees and welcome bachelor students in Biopharma and Bioquality apprenticeships”, Laurent Simonart, Talent Country Lead, Belgium.